Side effects and pharmaceutical company bias: adverse event reporting in cancer supportive and palliative care trials

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.17, Iss.12, 2008-12, pp. : 1787-1790

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Effects of Stratification on Data Mining in the US Vaccine Adverse Event Reporting System (VAERS)

By Emily Jane Woo Ball Robert Burwen Dale R. Braun M. Miles

Drug Safety, Vol. 31, Iss. 8, 2008-01 ,pp. : 667-674

Adis International

Access to resources Recommend Favorite

A review of the Vaccine Adverse Event Reporting System database

By Geier David A Geier Mark R

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 3, 2004-03 ,pp. : 691-698

Informa Healthcare

Access to resources Recommend Favorite

Commentary: Advocating for Mandatory Adverse Event Reporting

By Hanke C. William

Dermatologic Surgery, Vol. 38, Iss. 2, 2012-02 ,pp. : 178-179

Elsevier

Access to resources Recommend Favorite

Introduction of pharmaceutical expertise in a palliative care team in Sweden

By Norrström Barbro

Pharmacy World and Science, Vol. 32, Iss. 6, 2010-12 ,pp. : 829-834

Springer Publishing Company

Access to resources Recommend Favorite

Tackling the Challenges of Clinical Trials in Palliative Care

By Currow David C. Agar Meera R. Abernethy Amy P.

Pharmaceutical Medicine, Vol. 25, Iss. 1, 2011-02 ,pp. : 7-15

Adis International

Access to resources Recommend Favorite